T-cell

The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted Promising Innovative Medicine (PIM) designation to Autolus Therapeutics plc's (NASDAQ: AUTL) AUTO1 (obecabtagene autoleucel, obe-cel). The Company's CAR T cell therapy is being investigated...

Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) shares were advancing strongly Friday following an updated clinical readout from the company. Adaptimmune Reports Durable Responses With T-Cell Therapy The Philadelphia-based company said updated data from its Phase 1 study dubbed SPEARHEAD-1...

• ZIOPHARM Oncology Inc. (NASDAQ: ZIOP) CEO Dr. Laurence Cooper believes that the company’s cell programming languages set it apart from other cancer researchers. • The company’s Sleeping Beauty platform allows for T cell modification without the use of a viral...

Kite Pharma Inc (NASDAQ: KITE) recently announced that it will be partnering with bluebird bio Inc (NASDAQ: BLUE) to develop second-generation, T-cell receptor product candidates. Arie Belldegrun, Kite Pharma CEO, was recently on CNBC to shed some light on T-cell therapy the company is...